Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88 L265P Mutation
The B-cell receptor signaling pathway is important in the lymphomagenesis of many lymphomas, including marginal zone lymphoma (MZL). Herein we describe a case of extranodal MZL refractory to multiple lines of therapy. The presence of an IgM paraprotein prompted further evaluation, and the patient was found to have an MYD88L265P mutation. Treatment with ibrutinib led to a dramatic response with prompt resolution of symptoms and significant improvement in measurable sites of disease. The excellent response to ibrutinib in our patient with MYD88L265P-mutated refractory MZL supports a biological rationale for its use.Case Rep Oncol 2017;10:813 –818
We describe an interesting case of a 39-year-old woman who presented with mucinous adenocarcinoma that originated in the thymus and was treated via radical resection and venoplasty of the superior vena cava (SVC). Macroscopically, the resected tumor contained a solid region and multiple cysts with abundant mucin. Microscopic examination showed a papillary growth pattern of goblet cells with round nuclei. Based on the histopathological and immunohistochemical findings and other inspections, the tumor was eventually diagnosed as a mucinous adenocarcinoma of the thymus. It was classified as Masaoka-Koga stage III owing to tum...
Conclusion The use of RT in NLPHL is less likely among those with advanced-stage and B-symptoms. However, we found RT to be associated with prolonged OS in all stages of NLPHL, including those with B-symptoms. Teaser We assessed the role of radiotherapy (RT) in nodular lymphocytic Hodgkin lymphoma (NLPHL), particularly among patients with advanced stage disease, and B symptoms. We found that among NLPHL patients, RT had a potential role in advanced-stage disease and those with B symptoms, suggesting further exploratory studies.
Publication date: Available online 23 September 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): José L. Ortega, Fernando Cabanillas, Noridza Rivera, Maribel Tirado-Gomez, Deana Hallman, Wandaly I. Pardo, Margarita Bruno
Conclusion A single-institutional retrospective analysis found no significant differences in outcomes using GCLAC or CLAG for rrAML patients, though formal comparisons should be performed in a randomized clinical trial. The cost of GCLAC was higher than CLAG which should be considered when evaluating salvage chemotherapy options.
Conclusion: The findings of the current study prove the protective role of taurine in NAFLD via a novel role in the amelioration of FGF-21/ SIRT1 axis, which could be considered a new therapeutic target.Cell Physiol Biochem 2017;43:644 –659
Yu-Hsiang Lee, Juin-Hua Huang, Tzu-Hsuan Chang, Hung-Chih Yang, Betty A. Wu-Hsieh
Roche announced today that the European Commission has approved Gazyvaro ® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment for previously untreated advanced follicular lymphoma.
AbstractOcular adnexal lymphomas are a group of heterogeneous neoplasms representing approximately 1 –2% of non-Hodgkin lymphomas and 8% of extranodal lymphomas. The incidence of primary ocular adnexal lymphoid tumors has raised over the last decades, and this could be probably attributed to the more sophisticated diagnostic techniques. Due to the wide spectrum of clinical manifestations, ocular tissue biopsy is important in order to set a precise diagnosis based on histological, immunophenotypical and, in some cases, molecular findings. The most common subtype, which may account for up to 80% of primary ocular adnex...
Activation of RHOA–VAV1 signaling in angioimmunoblastic T-cell lymphoma Leukemia advance online publication, September 22 2017. doi:10.1038/leu.2017.273 Authors: M Fujisawa, M Sakata-Yanagimoto, S Nishizawa, D Komori, P Gershon, M Kiryu, S Tanzima, K Fukumoto, T Enami, M Muratani, K Yoshida, S Ogawa, K Matsue, N Nakamura, K Takeuchi, K Izutsu, K Fujimoto, T Teshima, H Miyoshi, P Gaulard, K Ohshima &S Chiba
Abhishek De, Tanumay Raychaudhury, Murlidhar Rajagopalan, Aarti Sarda, Nidhi SharmaIndian Journal of Dermatology 2017 62(5):533-535